Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?

PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).

BGI Genomics report: Thailand needs to take urgent action to combat cervical cancer

Only 28.5% of Thai women are diagnosed at stage I of cervical cancer when survival rates are highest, according to a study published by the

August 1, 2023

Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of – Biotech Investments

EQS-News: Affluent Medical SA / Key word(s): Capital Increase Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares

July 16, 2024

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

AstraZeneca and Daiichi Sankyo are changing the approval submission strategy for its planned Enhertu successor, datopotamab deruxtecan (Dato-DXd), after a few missed trials. The companies

November 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.